TRDA — Entrada Therapeutics Inc
NASDAQ · Biotechnology · Biotechnology
- Latest Close
- $13.05
- 30-Day Move
- +20.7%
- Market Cap
- $461M
- Shares Outstanding
- 38,280,000
- P/B Ratio
- 1.28
- ROE
- -47.0%
Entrada Therapeutics Inc
A read-only Alphactor snapshot forEntrada Therapeutics Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-22
Topline snapshot
Latest Close
$13.05
30-Day Move
+20.7%
Market Cap
$461M
Shares Outstanding
38,280,000
P/B Ratio
1.28
ROE
-47.0%
$13.05
+20.7%last 90 delayed daily bars
90D High
$14.49
90D Low
$9.33
Avg Volume
206,202
Net margin is -565.5%, useful for comparing TRDA against peers in Biotechnology.
TRDA is up 20.7% over the last 30 trading days shown on this page.
Latest operating income is $-42M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$4.35
Rule of 40
-597.6%
Latest Close
$13.05
30-Day Move
+20.7%
Market Cap
$461M
Shares Outstanding
38,280,000
P/B Ratio
1.28
ROE
-47.0%
ROA
-38.1%
Operating Margin
-621.1%
Net Margin
-565.5%
Debt / Equity
0
Current Ratio
12.53
Latest Revenue
$1M
Revenue
$1M
Gross Profit
--
Operating Income
$-42M
Net Income
$-39M
Gross Margin
--
Net Margin
-56548.0%
Current Ratio
12.53
Debt / Equity
0.00
Fair Value
$4.35
Upside / Downside
-66.7%
Signal
Overvalued
Implied Growth
--
EV/Rev
$4.35
Growth Assumption
5.0%
Discount Rate
10.5%
Terminal Growth
2.0%
Base FCF
--
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative FCF — company is cash-flow negative. Reverse DCF requires positive cash flows.
Altman Z
2.45
Grey
Piotroski
2
Weak (0-3)
Cash Conversion
0.89x
Rule of 40
-597.6%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $0 | $-97M | $-95M | $-97M |
| 2023-12-31 | $129M | $-3M | $-7M | $134M |
| 2024-12-31 | $211M | $47M | $66M | $-45M |
| 2025-12-31 | $25M | $-158M | $-144M | $-130M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Buy Value
$2M
Sell Value
$6M
Buys
16
Sells
25
Buy Value
$2M
Sell Value
$6M
Buy/Sell Ratio
0.64x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-01 | WENTWORTH KORY JAMES | Sell | 2,500 | $12.95 |
| 2026-03-10 | Dowden Nathan J | Sell | 11,894 | $13.05 |
| 2026-03-10 | WENTWORTH KORY JAMES | Sell | 11,388 | $13.02 |
| 2026-03-09 | Dowden Nathan J | Sell | 3,116 | $13.02 |
| 2026-03-09 | WENTWORTH KORY JAMES | Sell | 5,089 | $13.00 |
| 2026-03-04 | WENTWORTH KORY JAMES | Sell | 7,988 | $12.25 |
| 2026-03-03 | Sethuraman Natarajan | F | 7,577 | $11.76 |
| 2026-03-03 | Dowden Nathan J | F | 14,038 | $11.76 |
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 953,727 | 0.02% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 693,348 | 0.02% | 2026-02-28 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 274,830 | 0.01% | 2026-01-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 255,353 | 0.01% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 Value ETF | 247,295 | 0.01% | 2026-02-28 |
| T. Rowe Price Health Sciences Fund, Inc. | 171,368 | 0.00% | 2025-12-31 |
| ROYCE CAPITAL FUND-Royce Capital Fund - Small-Cap Portfolio | 157,249 | 0.00% | 2025-12-31 |
| iShares Trust-iShares Biotechnology ETF | 158,499 | 0.00% | 2026-02-28 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Two Sigma Advisers
Filed 2026-02-17
--
--
BlackRock
Filed 2024-08-13
$24M
--
Vanguard Group
Filed 2026-01-29
$17M
+1.8%
Geode Capital Management
Filed 2026-02-09
$7M
-0.8%
Renaissance Technologies
Filed 2025-11-13
$3M
+56.6%
Citadel Advisors
Filed 2026-02-17
$3M
--
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.